CV6 to Present Details of Ongoing Phase 1a Clinical Trial at 2024 ASCO Annual Meeting
CV6 Announces Initiation of Patient Dosing in Phase 1a Clinical Trial Evaluating
the Investigational First-In-Class, Specific dUTPase Inhibitor CV6-168.
CV6 Therapeutics (NI) Ltd. (“CV6”), a clinical-stage pharmaceutical company dedicated to improving the lives of patients with cancer and inflammatory diseases by developing novel, first-in-class, small molecules targeting Uracil-DNA metabolism, today announced the successful dosing of the second patient in its Phase 1a study evaluating CV6-168 + infusional 5-fluorouracil (5-FU) in cancer patients.
This Phase 1 part of this modular, first-in-human Phase 1a clinical trial (ISRCTN12434145) is a multicenter, open-label, dose-escalation study of CV6-168 in patients with advanced metastatic solid tumors refractory to standard treatment. The primary objectives of the study are to determine the following parameters for CV6-168: safety profile, potential optimal biologically relevant doses, maximum tolerated dose, and anti-tumor activity.
CV6-168 is a novel, targeted, small molecule, dUTPase-specific inhibitor in development for the treatment of multiple, high-incidence cancers. In preclinical studies, it has demonstrated robust anti-tumor activity in cell line and animal models with no added toxicity. CV6-168 targets the nucleotide metabolism enzyme dUTPase, with high specificity, avoiding drug-drug interactions with its drug combination partners that include thymidylate synthase (TS) inhibitors like 5-fluorouracil (5-FU).
You might also like
View all
Test Press Release
Lorem ipsum dolor sit amet consectetur. Id mi eu non elementum lectus. Lorem turpis morbi varius amet. Convallis sed pretium vitae rhoncus elit. Sed at ut quisque massa faucibus nisl eget...
Test Media
Lorem ipsum dolor sit amet consectetur. Id mi eu non elementum lectus. Lorem turpis morbi varius amet. Convallis sed pretium vitae rhoncus elit. Sed at ut quisque massa faucibus nisl eget...